ALiA BioTech’s rapid diagnostic platform is capable of providing up to 30 accurate results from a single drop of body fluid – whether it be blood, serum, swab or urine. Forget lengthy waiting times and inaccurate results; with this revolutionary platform, you can get the answers you need in no time.
The Covid-19 pandemic has created a surge in the demand for point-of-care testing (POCT) – almost doubling the size of the market compared to pre-pandemic levels. Multiplexing is the key technology that sets the market apart, and ALiA BioTech group has answered the call with a revolutionary rapid diagnostic platform capable of conducting up to 15 simultaneous assays in a single biochip within 15 minutes. This cutting-edge diagnostics tool has the potential to revolutionize the way we respond to future outbreaks.
We all have that moment of fear when we sneeze or cough – are we catching something? With Covid-19, influenza, respiratory syncytial virus, and Streptococcus pneumoniae all circulating, it’s hard to know for sure. But thanks to our platform, you can get the answers you need quickly and accurately with just one test. Kelvin Chiu, CEO of the company, understands how important this is – it’s now personal.
ALiA’s groundbreaking Lab-on-Chip platform is revolutionizing Point-of-Care-Testing (POCT). This patented technology allows for up to 30 results from a single drop of body fluid, be it blood, serum, swab, or urine. Having perfected their proprietary microfluidic and microarray technologies, ALiA is now ready to bring their multiplex products for different disease panels to a larger market. Moreover, the company’s pipeline is also exploring the possibilities of POCT for veterinary health and agri-food surveillance.
ALiA’s biochip panels for respiratory infection and tropical fever have earned Europe’s coveted CE marks, demonstrating their commitment to providing the highest quality medical devices through their ISO 13485 certified quality management system.
The biotech firm is surging ahead with ambitious plans to expand into global markets and develop groundbreaking biochips for disease diagnosis. Regulatory approval is being secured in the US, mainland China and Southeast Asia, and the company is looking to forge strategic partnerships to further product development and commercialisation. Additionally, the firm is keen to explore opportunities to establish advanced manufacturing facilities in the US, EU and Asia-Pacific.
In the next decade, we are committed to introducing rapid diagnostic panels that will revolutionize healthcare – saving lives in real-time. To do this, we will develop multiplex disease panels, conduct clinical trials, and gain regulatory approval. This is an ambitious goal, but one that we are fully prepared to reach.
About ALiA BioTech group
The ALiA BioTech group is on a mission to revolutionize the way medical professionals and front-line workers respond to diseases. By assembling a strong and diverse team from Hong Kong, China, France, and the United States, we are paving the way for faster diagnosis and better management of diseases. With cutting-edge innovations, we are determined to shape the future of disease diagnostics.